{
    "organizations": [],
    "uuid": "c33e4947e45e6f53ce077723a654a5be31609cbc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gensight-biologics-receives-mhra-a/brief-gensight-biologics-receives-mhra-approval-to-initiate-phase-i-ii-pioneer-clinical-trial-of-gs030-gene-therapy-in-retinitis-pigmentosa-idUSASM000HYV",
    "ord_in_thread": 0,
    "title": "BRIEF-GenSight Biologics Receives MHRA Approval To Initiate Phase I/II Pioneer Clinical Trial Of GS030 Gene Therapy In Retinitis Pigmentosa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Gensight Biologics SA:\n* GENSIGHT BIOLOGICS RECEIVES MHRA APPROVAL TO INITIATE PHASE I/II PIONEER CLINICAL TRIAL OF GS030 GENE THERAPY IN RETINITIS PIGMENTOSA ",
    "published": "2018-01-10T22:51:00.000+02:00",
    "crawled": "2018-01-11T12:41:22.061+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "gensight",
        "biologics",
        "sa",
        "gensight",
        "biologics",
        "receives",
        "mhra",
        "approval",
        "initiate",
        "phase",
        "pioneer",
        "clinical",
        "trial",
        "gs030",
        "gene",
        "therapy",
        "retinitis",
        "pigmentosa"
    ]
}